Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
Rhea-AI Summary
Aclarion (Nasdaq: ACON) expanded Nociscan availability by establishing an agreement with Source Healthcare in Los Angeles on Feb 3, 2026 to integrate Nociscan into the clinic’s spine and pain pathways.
The partnership will generate real-world evidence comparing Nociscan to anesthetic discography and aims to strengthen clinical validation and payer/provider adoption for the non-invasive MR spectroscopy test.
Positive
- Agreement to deploy Nociscan at Source Healthcare, Los Angeles
- Real-world evidence study comparing Nociscan versus anesthetic discography
- Non-invasive MR spectroscopy alternative to diagnostic discography
- Cited 97% surgical success rate when Nociscan-positive discs are treated
Negative
- Evidence in pain-management field is currently being established, not yet proven
- No financial impact, revenue, or commercialization metrics disclosed in announcement
Key Figures
Market Reality Check
Peers on Argus
ACON fell 12.99% while close peers showed mixed moves: WORX down 10%, BFRG down 7.14%, POAI flat, VSEE up 3.98%, DRIO up 8.64%. With no peers in the momentum scanner and no same-day peer headlines, the move appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Financing / runway | Positive | -6.9% | Closed $10.4M equity financing, extended cash runway into 2028 with no debt. |
| Jan 08 | Outlook update | Positive | +42.1% | 2026 outlook, strong 2025 Nociscan volume growth and cash runway into H1 2027. |
| Jan 06 | Clinical trial progress | Positive | +3.7% | First enrollments at additional CLARITY sites and guidance on interim data timing. |
| Dec 04 | Clinical publication | Positive | +5.0% | Nociscan case report published in IJSS special pain issue highlighting clinical utility. |
| Dec 02 | Commercial hire | Positive | +10.3% | Appointment of Eastern U.S. Commercial Director to drive Nociscan adoption and payers. |
Recent Nociscan- and strategy-focused updates generally saw positive price reactions, while the January financing-related balance sheet strengthening drew a negative response.
Over the past few months, Aclarion has consistently highlighted progress around its Nociscan platform and clinical strategy. Updates included CLARITY trial site activations and timelines, publication of a Nociscan case in the International Journal of Spine Surgery, and a commercial leadership hire to drive Eastern U.S. expansion. Financially, the company completed equity financings and reported modest but growing revenue. Today’s announcement about adding a high-volume Los Angeles practice and generating real-world evidence fits this ongoing commercialization and evidence-building trajectory for Nociscan.
Market Pulse Summary
This announcement adds a high-volume Los Angeles pain practice to Aclarion’s Nociscan footprint and establishes real-world evidence comparing the test with anesthetic discography. It builds on earlier CLARITY trial progress, published case data, and commercial expansion efforts. Key factors to watch include further adoption by multidisciplinary pain centers, additional peer-reviewed evidence, and how new data influence payer and provider decisions, especially given the large cLBP population of 266 million and reported 97% surgical success rate for Nociscan-positive discs.
Key Terms
mr spectroscopy medical
biomarkers medical
saas platform technical
AI-generated analysis. Not financial advice.
- Expands availability of Nociscan in the greater Los Angeles area
- Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedure
- Supports scalable growth strategy while building data assets critical to payer and provider adoption
BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today it has established an agreement with Source Healthcare, a state-of-the-art orthopedic and regenerative health clinic in Los Angeles to help address a key gap in addressing low back pain.
The agreement aligns with Aclarion’s expansion strategy by bringing Nociscan to Source Healthcare and the multidisciplinary team led by interventional pain management specialist, Timothy T. Davis, MD. Moreover, the growing evidence base for Nociscan will be strengthened by adding a high-volume clinical practice where real-world evidence comparing Nociscan and anesthetic discography will be generated. An anesthetic discogram is a diagnostic spinal injection procedure used to identify specific spinal disc(s) causing chronic pain. Nociscan is a non-invasive alternative that objectively measures pain and structural integrity biomarkers in spinal discs through an MRI-like experience for the patient.
“Our team at Source Healthcare emphasize holistic-care and science backed solutions for pain relief of those suffering from spine and chronic pain,” said Tim Davis, MD, interventional pain management specialist and founder of Source Healthcare. “We see and treat a lot of patients with chronic low back pain and degenerative disc disease. Historically, we have used lumbar MRI and anesthetic discography with good results. We are excited to gain access to Nociscan, a MR Spectroscopy test that objectively evaluates various pain and structural integrity biomarkers non-invasively, something not available from MRI or discography. We believe this test will become a valuable part of our care pathways.”
“Nociscan has demonstrated improved outcomes and lower costs in peer-reviewed published literature when studied in the spinal fusion market. This study is our first opportunity to establish evidence within the much larger pain management field,” stated Ryan Bond, Chief Strategy Officer of Aclarion. “We are pleased to be working with Dr. Davis, a true leader in the field of Pain Management, on this seminal real-world evidence work.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
FAQ
What did Aclarion (ACON) announce about Nociscan on February 3, 2026?
How will the Source Healthcare agreement affect Nociscan clinical evidence for ACON?
What is Nociscan and how does it compare to anesthetic discography for ACON?
Does Aclarion claim clinical effectiveness for Nociscan (ACON)?
Will the Source Healthcare partnership expand patient access to Nociscan for ACON?
